MXPA99007373A - Cosmetic and/or dermatological composition containing salicylic acid or its derivatives and its use - Google Patents
Cosmetic and/or dermatological composition containing salicylic acid or its derivatives and its useInfo
- Publication number
- MXPA99007373A MXPA99007373A MXPA/A/1999/007373A MX9907373A MXPA99007373A MX PA99007373 A MXPA99007373 A MX PA99007373A MX 9907373 A MX9907373 A MX 9907373A MX PA99007373 A MXPA99007373 A MX PA99007373A
- Authority
- MX
- Mexico
- Prior art keywords
- acid
- glucose
- composition according
- ester
- skin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 82
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 239000002537 cosmetic Substances 0.000 title claims abstract description 20
- 229960004889 salicylic acid Drugs 0.000 title claims abstract description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 42
- 239000008103 glucose Substances 0.000 claims abstract description 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 34
- -1 fatty acid ester Chemical class 0.000 claims abstract description 32
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 26
- 239000000194 fatty acid Substances 0.000 claims abstract description 26
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 20
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 19
- 239000007764 o/w emulsion Substances 0.000 claims abstract description 4
- 210000003491 Skin Anatomy 0.000 claims description 38
- 150000002148 esters Chemical class 0.000 claims description 24
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 claims description 17
- HOVAGTYPODGVJG-WLDMJGECSA-N Methylglucoside Chemical compound COC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-WLDMJGECSA-N 0.000 claims description 17
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 16
- 210000004400 Mucous Membrane Anatomy 0.000 claims description 9
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 9
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims description 9
- 230000037303 wrinkles Effects 0.000 claims description 9
- 230000032683 aging Effects 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 206010000496 Acne Diseases 0.000 claims description 6
- 102000011782 Keratins Human genes 0.000 claims description 6
- 108010076876 Keratins Proteins 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 150000002170 ethers Chemical class 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- PCGKIWPTIJPQHI-UHFFFAOYSA-N 16-methyloctadecanoic acid Chemical compound CCC(C)CCCCCCCCCCCCCCC(O)=O PCGKIWPTIJPQHI-UHFFFAOYSA-N 0.000 claims description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N Lauric acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 208000006641 Skin Disease Diseases 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 150000002194 fatty esters Chemical class 0.000 claims description 3
- 239000003349 gelling agent Substances 0.000 claims description 3
- 238000009499 grossing Methods 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-hydroxystearic acid Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 claims description 2
- 239000005639 Lauric acid Substances 0.000 claims description 2
- 210000003666 Nerve Fibers, Myelinated Anatomy 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- CJYBKFFVXWWBMY-UHFFFAOYSA-N dodecyl 2-hydroxybenzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1O CJYBKFFVXWWBMY-UHFFFAOYSA-N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- NHLHASWXBVULGU-UHFFFAOYSA-N hexadecyl 2-hydroxybenzoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1O NHLHASWXBVULGU-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- VLMWBWYAHNRUGC-UHFFFAOYSA-N tridecyl 2-hydroxybenzoate Chemical compound CCCCCCCCCCCCCOC(=O)C1=CC=CC=C1O VLMWBWYAHNRUGC-UHFFFAOYSA-N 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- MFSJUURIAOOSJR-UHFFFAOYSA-N 2-hydroxy-5-(2,4,4-trimethylpentan-2-yl)benzoic acid Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(O)C(C(O)=O)=C1 MFSJUURIAOOSJR-UHFFFAOYSA-N 0.000 claims 1
- DLGBEGBHXSAQOC-UHFFFAOYSA-N 2-hydroxy-5-methylbenzoic acid Chemical compound CC1=CC=C(O)C(C(O)=O)=C1 DLGBEGBHXSAQOC-UHFFFAOYSA-N 0.000 claims 1
- VHCJSVNQEBEVMO-UHFFFAOYSA-N 2-hydroxy-5-propoxybenzoic acid Chemical compound CCCOC1=CC=C(O)C(C(O)=O)=C1 VHCJSVNQEBEVMO-UHFFFAOYSA-N 0.000 claims 1
- IZZIWIAOVZOBLF-UHFFFAOYSA-N 5-Methoxysalicylic acid Chemical compound COC1=CC=C(O)C(C(O)=O)=C1 IZZIWIAOVZOBLF-UHFFFAOYSA-N 0.000 claims 1
- AHOYBBZASFMDDD-UHFFFAOYSA-N 5-butoxy-2-hydroxybenzoic acid Chemical compound CCCCOC1=CC=C(O)C(C(O)=O)=C1 AHOYBBZASFMDDD-UHFFFAOYSA-N 0.000 claims 1
- ZZKFPIOJAOEMQL-UHFFFAOYSA-N 5-ethoxy-2-hydroxybenzoic acid Chemical compound CCOC1=CC=C(O)C(C(O)=O)=C1 ZZKFPIOJAOEMQL-UHFFFAOYSA-N 0.000 claims 1
- WYIAFSIUYJGIPU-UHFFFAOYSA-N 5-ethyl-2-hydroxybenzoic acid Chemical compound CCC1=CC=C(O)C(C(O)=O)=C1 WYIAFSIUYJGIPU-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 239000000839 emulsion Substances 0.000 description 17
- 239000012071 phase Substances 0.000 description 15
- 229940058287 Salicylic acid derivative anticestodals Drugs 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 5
- 210000004209 Hair Anatomy 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- IRLPACMLTUPBCL-KQYNXXCUSA-N 5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O IRLPACMLTUPBCL-KQYNXXCUSA-N 0.000 description 3
- 210000000088 Lip Anatomy 0.000 description 3
- FMJSMJQBSVNSBF-UHFFFAOYSA-N Octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N Stearyl alcohol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 229960000601 octocrylene Drugs 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 230000002335 preservative Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- XDOFQFKRPWOURC-UHFFFAOYSA-M 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC([O-])=O XDOFQFKRPWOURC-UHFFFAOYSA-M 0.000 description 2
- 229940044591 METHYL GLUCOSE DIOLEATE Drugs 0.000 description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl methoxycinnamate Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 2
- 210000004761 Scalp Anatomy 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- 201000004624 dermatitis Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 230000000475 sunscreen Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- KIHBGTRZFAVZRV-UHFFFAOYSA-M 2-hydroxystearate Chemical compound CCCCCCCCCCCCCCCCC(O)C([O-])=O KIHBGTRZFAVZRV-UHFFFAOYSA-M 0.000 description 1
- LKLYETYHDMXRAF-UHFFFAOYSA-N 2-octanoyloxybenzoic acid Chemical compound CCCCCCCC(=O)OC1=CC=CC=C1C(O)=O LKLYETYHDMXRAF-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N Avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229940049657 CYCLOMETHICONE 5 Drugs 0.000 description 1
- 208000003643 Callosity Diseases 0.000 description 1
- 229960001631 Carbomer Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 240000005801 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 240000005497 Cyamopsis tetragonoloba Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- GJQLBGWSDGMZKM-UHFFFAOYSA-N Ethylhexyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(CC)CCCCC GJQLBGWSDGMZKM-UHFFFAOYSA-N 0.000 description 1
- 210000000720 Eyelashes Anatomy 0.000 description 1
- 210000000744 Eyelids Anatomy 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000006669 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010021198 Ichthyosis Diseases 0.000 description 1
- 206010021197 Ichthyosis Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Natural products CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 210000000282 Nails Anatomy 0.000 description 1
- 208000006551 Parasitic Disease Diseases 0.000 description 1
- 240000008426 Persea americana Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229940066842 Petrolatum Drugs 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 240000003670 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- 206010040943 Skin ulcer Diseases 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N Sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229960003080 Taurine Drugs 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical class [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003712 anti-aging Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 230000003385 bacteriostatic Effects 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 231100000406 dermatitis Toxicity 0.000 description 1
- 229940042397 direct acting antivirals Cyclic amines Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000009754 grape Nutrition 0.000 description 1
- 235000012333 grape Nutrition 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl radical Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 230000001530 keratinolytic Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 125000005645 linoleyl group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000005426 persea americana Nutrition 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical class [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Abstract
A new cosmetic or dermatological composition is an oil-in-water emulsion comprises:(a) salicylic acid and/or at least one of its derivatives;(b) at least one fatty acid ester of glucose and/or alkylglucose;and (c) at least one oxyethylenated ether of a fatty acid and glucose and/or alkylglucose.
Description
COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING SALICYLIC ACID OR A DERIVATIVE OF SALICYLIC ACID AND ITS
UTILIZATION
The invention relates to a cosmetic and / or dermatological composition in the form of an oil-in-water emulsion, based on salicylic acid and / or a salicylic acid derivative, which contains an ester of glucose or alkyl glucose and an oxyethylenated ether of glucose and / or alkyl glucose. It also refers to the use of this composition to combat, little by little, against the aging of the skin of the face and / or of the human body, including the scalp, and to combat acne and / or skin changes. . It is known to use beta-hydroxy acids and particularly salicylic acid and its derivatives as keratolytic agents for treating acne and as anti-aging agents in cosmetic and / or dermatological compositions. Thus, WO-A-93/10756 describes the use of a composition, based on salicylic acid to treat wrinkles and documents FR-A-2 581 542 and EP-A-378 936 describe the use of derivatives of salicylic acid to treat acne and the signs of aging. Salicylic acid and its derivatives are from a
REF 30865 great interest, given that its biological effects on the skin, particularly on the main clinical signs of skin aging, such as fine lines and wrinkles, the disorganization of the "grain" of the skin, the modification of the color of the skin and the loss of firmness and tonicity of the skin. In addition, the salicylic acid derivatives have the advantage in relation to salicylic acid, to have a higher keratolytic activity and an effective bacteriostatic activity. Unfortunately, the use of these active agents poses a problem insofar as they can cause itching, itching, tightness after application, and may lead to significant discomfort. The use of these compounds for users with sensitive skin is, therefore, often redhibitory or harmful. In addition, it is often necessary to add to these compounds, solvents such as octyldodecanol, to solubilize them, they can be added for the discomfort of the composition that contains them. Also, there remains a need for a cosmetic and / or dermatological composition based on such compounds, which does not have the drawbacks of the prior art. The Applicant has unexpectedly found that the tolerance of salicylic acid and its derivatives can be significantly increased by incorporating them into an oil-in-water (H / E) emulsion, emulsion having a pH of 4 or more. , and containing as surfactants a mixture of glucose ester or alkyl glucose and oxyethylenated glucose or alkyl glucose. The subject of the present invention is therefore a cosmetic and / or dermatological composition in the form of an oil-in-water emulsion, characterized in that it has a pH between 4 and 7 and contains (i) salicylic acid and / or at least a derivative of salicylic acid, (ii) at least one ester of fatty acid and of glucose and / or of alkyl glucose, and (iii) at least one oxyethylenated ether of fatty acid and of glucose and / or of alkyl glucose. The combination of an ester of (alkyl) glucose and an oxyethylenated ether of (alkyl) glucose makes it possible to obtain a perfectly tolerated composition when it is applied to the skin of the face and / or of the human body. This combination is, accordingly, a preferred embodiment used as a single surfactant. The fatty chain in the fatty acid ester and
(alkyl) glucose and the fatty chain in the oxyethylenated ether of fatty acid and (alkyl) glucose preferably comprise from 8 to 30 carbon atoms and more particularly from 10 to 22 carbon atoms.
As the fatty acid ester and the glucose or alkyl glucose ester, mention may in particular be made of the fatty esters of methylglucoside and more especially of the diester of methylglucoside and oleic acid (CTFA name: Methyl glucose dioleate); the mixed ester of methylglucoside and the mixture of oleic acid / hydroxystearic acid (CTFA name: Methyl glucose dioleate / hydroxystearate); the ester of methylglucoside and isostearic acid (CTFA name methyl glucose isostearate); the ester of methylglucoside and lauric acid (CTFA name: Methyl glucose laurate); the ester of methylglucoside and isostearic acid (CTFA name: Methyl glucose isostearate); the mixture of monoster and diester of methylglucoside and isostearic acid (CTFA name: Methyl glucose sesquiisostearate); the mixture of monoster and diester of methylglucoside and stearic acid (CTFA name: Methyl glucose sesquifiscaterate) and in particular the product marketed under the name Glucate SS by the company AMERCHOL. A mixture of these esters can also be used. Preferably, the fatty acid and glucose ester or alkyl glucose ester is introduced into the oily phase of the emulsion. It is used in a satisfactory amount to ensure the expected result. Thus, this amount can range, for example, between 0.1% and 10% by weight and preferably between 1% and 3% by weight relative to the total weight of the composition. The oxyethylenated ether of fatty acid and of glucose or alkyl glucose preferably comprises from 10 to 100 oxyethylenated groups (or moles of ethylene oxide) and better than 20 to 40 oxyethylenated groups. Oxyethylenated ethers of fatty acid and of glucose or alkyl glucose can be, for example, the oxyethylenated ethers of fatty acid and of methyl glucose and in particular the polyethylene glycol ether of methyl glucose and stearic acid in approximately 20 moles of sodium oxide. ethylene (CTFA name: PEG-20 methyl glucose distearate) such as the product marketed under the name Glucam E-20 distearate by the AMERCHOL Company; the polyethylene glycol ether of the monoster and diester mixture of methyl glucose and stearic acid in approximately 20 moles of ethylene oxide (CTFA name: PEG-20 methyl glucose sesquistearate) and in particular the product marketed under the name Glucamate SSE- 20 by the AMERCHOL Company and the one marketed under the name Grillocose PSE-20 by the GOLDSCHMIDT Company. A mixture of these oxyethylenated ethers can also be used. Preferably, the oxyethylenated ether of (alkyl) glucose is introduced into the aqueous phase of the emulsion. It is used in a satisfactory amount to ensure the expected result. The amount of oxyethylenated ether (s) of fatty acid and (alkyl) glucose can range, for example, from 0.1% to 10% by weight and preferably from 1% to 3% by weight relative to the total weight of the composition. The composition of the invention may comprise salicylic acid and / or one or more salicylic acid derivatives. As salicylic acid derivatives, any derivative capable of being used in a cosmetic and / or dermatological composition can be used, and particularly the salicylic acid derivatives of formula (I) or a salt of said derivative:
wherein: Ri represents hydrogen or an aliphatic chain, alkoxy, ester or ketoxy, saturated, linear, branched or cyclized, an unsaturated chain bearing one or more double bonds conjugated or not, these chains comprising from 1 to 22 carbon atoms and being able to be substituted by at least one substituent selected from the halogen atoms, the trifluoromethyl group, the hydroxyl groups in free form or esterified by an acid having from 1 to 6 carbon atoms or by a carboxyl function, free or esterified by an inferior alcohol having from 1 to 6 carbon atoms; R2 represents a hydroxyl group or an ester function of formula (II):
where R4 represents a saturated aliphatic group or an alkenyl group having from 1 to 18 carbon atoms; R3 represents hydrogen or a straight or branched chain, saturated or unsaturated, having 2 to 30 carbon atoms, optionally comprising one or more substituents. The chain can be selected in particular from alkyl and alkenyl radicals comprising from 2 to 30 carbon atoms, optionally substituted. The substituent can be in particular a hydroxyl radical. When R3 is hydrogen, salts of the acids of formula (I) can also be used, and in particular salts obtained by salification with a base.
As a base capable of salifying the salicylic acid derivatives of formula (I), mention may be made of mineral bases such as alkali metal hydroxides (sodium and potassium hydroxides) or ammonium hydroxides or, better still, organic bases such as organic primary, secondary, tertiary or cyclic amines and more especially amino acids. As an example of bases, glycine, the usin, arginine, taurine, histidine, alanine, valine, cysteine, trihydroxy-methylaminomethane (TRISTA), and triethanolamine may be mentioned. According to a particular embodiment of the invention, a derivative of formula (I) in which the radical Ri comprises at least 4 carbon atoms is used in the composition of the invention. It is for example formed by an alkyl radical or saturated linear alkoxy having from 4 to 11 carbon atoms. As derivatives of formula (I) in which R 2 is a hydroxyl and R 3 is hydrogen, mention may be made in particular of n-octanoyl-5-salicylic acid (CTFA name: Capryloyl Salicylic Acid), n-decanoyl-5-salicylic acid, n -dodecanoyl-5-salicylic, n-octyl-5-salicylic, n-heptyloxy-5-salicylic, 5-tert-octylsalicylic, 5-butoxysalicylic, 5-ethoxysalicylic, 5-methoxysalicylic, 5-propoxysalicylic, 5-methylsalicylic, 5 -ethylsalicylic, and 5-propylsalicylic, these acids being eventually salified by a base. When Ri represents hydrogen and R2 a hydroxyl group, the derivative of formula (I) is an ester of salicylic acid. Preference is given to esters of fatty alcohols, such as esters of dodecyl, hexadecyl, stearyl, cetyl, myristyl, linoleyl, octyl, oleic, tridecyl alcohols, or esters of butyl, propyl, ethyl alcohols, or even polyol esters such as esters of propylene glycol, butylene glycol, ethylene glycol or glycerol, or mixtures of these esters. It can be, in particular, cetyl salicylate, dodecyl salicylate and tridecyl salicylate. The salicylic acid and its derivatives are used in the composition according to the present invention, in sufficient quantity to achieve the expected cosmetic or dermatological result. The amount of salicylic acid and / or derivative (s) of salicylic acid preferably ranges between 0.001 and 10% by weight and better between 0.05 and 5% by weight relative to the total weight of the composition. The composition according to the invention has a pH between 4 and 7, and preferably between 4 and 6. A great compatibility of the emulsion of the invention with respect to the skin occurs.
The composition of the invention is intended for topical application and suitably comprises a physiologically acceptable medium. By physiologically acceptable means, means a medium compatible with the skin, mucous membranes (including the inside of the eyelids and lips), nails and / or keratin fibers (hair and eyelashes). The composition of the invention may contain, if necessary, a solvent to solubilize the salicylic derivative, such as octyldodecanol, certain glycols, short chain fatty alcohols (<; C12), or short chain esters (< C12). The composition of the invention is well tolerated even in the presence of such a solvent. The nature of the oily phase that enters the composition of the H / E emulsion is not critical and it can thus be constituted by all the fatty acids and particularly the oils, classically used in the cosmetic and / or dermatological fields. Among the oils that can be used in the emulsion of the invention, mention may be made, for example, of oils of vegetable origin (jojoba, avocado, sesame, sunflower, corn, soybean, safflower, grape seeds), mineral oils (petrolatum). , optionally hydrogenated isoparaffins), synthetic or synthetic oils (isopropyl myristate, cetearyl octanoate, polyisobutylene, ethylhexyl palmitate, alkylbenzoates), silicone oils (cyclomethicone such as cyclohexadimethylsiloxane, polydi ethylsiloxanes, polyethylphenylsiloxanes, polydimethylfluorosiloxanes ) and fluorinated oils. The other fatty acids which may be present in the oily phase may be, for example, fatty acids, fatty alcohols such as stearyl alcohol and waxes. The oily phase of the emulsion may represent from 1 to 50% and better from 5 to 40% by weight relative to the total weight of the composition. The aqueous phase of the emulsion may contain in particular one or more alcohols and / or polyols such as ethanol, glycerin, butylene glycol, isoprene glycol, propylene glycol, sorbitol, in concentrations preferably ranging from 1 to 20% by weight of the total weight of the composition. The aqueous phase generally represents from 1 to 80% and better from 30 to 70% by weight relative to the total weight of the composition. Furthermore, in a known manner, the compositions of the invention may contain adjuvants customary in the cosmetic and / or dermatological fields, such as the hydrophilic or lipophilic active agents, the preservatives, the antioxidants, the perfumes, the fillers, the coloring matters (pigments) or dyes), sunscreens, solvents and also lipid vesicles. These adjuvants are used in the usual proportions in the cosmetic or dermatological field, and for example between 0.01 and 20% of the total weight of the emulsion, and are, depending on their nature, introduced into the aqueous phase or the oily phase of the emulsion. the composition, or also in vesicles. Of course, the person skilled in the art will try to choose this or these possible additives and / or their amounts in such a way that the advantageous properties intrinsically related to the composition according to the invention are not, or substantially, altered by the addition (s) considered . As sunscreens, mention may be made, for example, of octocrylene (Uvinul N539 marketed by the BASF Company), octyl methoxycinnamate (Parsol MCX marketed by the Givaudan-Roure Company), butyl methoxydibenzoylmethane (Parsol 1789 marketed by the Givaudan-Roure Company) . As the solvent which can be used in the composition of the invention, mention may be made, for example, of octyldodecanol. Depending on the fluidity of the composition to be obtained, one or more gelling agents may be added, such as clays, polysaccharide gums and their derivatives (xanthan gum, carboxymethyl cellulose, hydroxypropyl guar), carboxyvinyl or carbomer polymers, polyacrylamides such as the one sold under the name SEPIGEL 305 by the SEPPIC Company and the polymers of at least partially crosslinked acrylamide ethylpropane sulphonic acid such as the product marketed under the name HOSTACERIN AMPS by the Company HOECHST. These gelling agents are generally used at concentrations ranging between 0.1 and 10%, preferably between 0.1 and 5% and better between 0.1 and 3% of the total weight of the composition. The Compositions, object of the invention, find their application in a large number of cosmetic and / or dermatological treatments of the skin, of the mucous membranes and / or of the hair included in the scalp, particularly for the protection, treatment, cleaning and / or make-up of the hair. skin and / or mucous membranes, for the protection and / or treatment of the hair and / or for the therapeutic treatment of the skin, of the hair and / or of the mucous membranes and more especially of the lips. The compositions according to the invention can for example be used in face treatment or cleansing products in the form of lotions, creams or milks, as make-up products (skin and lips) by incorporating fillers, pigments or dyes, or as solar composition by the incorporation of solar filter (s). The compositions of the invention have been shown particularly suitable for the treatment and / or make-up of the skin and / or mucous membranes and / or keratin fibers of the human being, and particularly for combating the signs of skin aging and / or for smoothing the skin of the face and / or body and / or to treat wrinkles and small wrinkles of the skin and / or to stimulate the epidermal renewal process and / or to treat acne and / or to treat skin disorders . They allow a little by little treatment of human skin. For skin disorders, it is understood in particular the area, burns, eczema, cutaneous parasitic disease, skin ulcer, fibrosis, control of scarring, psoriasis, pruritus, dermatitis, ichthyosis, callosities and the warts The invention also relates to a cosmetic treatment process for the protection, treatment, cleaning and / or make-up of the skin and / or mucous membranes and / or keratin fibers, consisting of applying to the skin. and / or mucous membranes and / or keratin fibers, a composition as defined above.
The subject of the invention is also a cosmetic treatment method for combating the signs of skin aging and / or improving the brightness of the color and / or smoothing the skin of the face and / or body and / or treating wrinkles and small wrinkles. wrinkles of the skin and / or stimulate the process of epidermal renewal, consisting in applying a composition on the skin as defined above. The subject of the invention is also the cosmetic use of the composition defined above for little by little treatment of human skin. The invention also aims to use the composition defined above for the manufacture of a dermatological composition intended to combat the signs of skin aging and / or to combat acne and / or to combat against skin disorders. Other features and advantages of the invention will be better understood from the examples that follow, given for illustrative purposes and not limiting. The proportions are given in percentage by weight.
Example 1: Cream A - Glucate SS [Amerchol] (Methyl Glucose Sesquistearate) 2%
Stearyl alcohol 1.5%
Cyclomethicone 10%
Hydrogenated Isoparaffin 7%
Octocrylene (Uvinul N539) 2%
Octyldodecanol 5%
Salicylic Capriloil 1%
Perfume 0.3%
B - Water csp 100%
Glycerin 5%
Glucamate SSE-20 [Amerchol] (PEG-20 Methyl glucose sesquistearate) 2%
Conservatives 0.6%
C - Hostacerin AMPS 1.2%
D - Sepigel 305 1%
Procedure: Phase A as well as phase B, were heated to
75 ° C until the perfect solubilization. Phase A was introduced into phase B under agitation, until a fine and regular emulsion was obtained. Phase C was added at 60 ° C and dispersed under stirring, then phase D was introduced in the same way. He refreshed himself under agitation. The cream obtained used in application on the skin, allows to increase the brightness of the color.
Example 2: Fluid Emulsion A - Glucate SS [Amerchol] (Methyl Glucose Sesquistearate) 1.5 Stearyl Alcohol 1 Cyclomethicone 5 Octocrylene (Uvinul N539) 2%
Octyldodecanol 3%
Salicylic Capriloil 0.5%
Perfume 0.2% Preservatives 0.1%
B - Water csp 100%
Glycerin 3%
Glucamate SSE-20 [Amerchol] (PEG-20 Methyl glucose sesquistearate) 1.5% Preservatives 0.5% C - Water 15%
Xanthan gum 0.1% D - Sepigel 305 1% Procedure: Phase A at 75 ° C was introduced in phase B at 75 ° C under agitation, until obtaining a fine and regular emulsion. Phase C was homogenized under stirring in water at 50 ° C then introduced under stirring at 50 ° C in mixture A + B. Phase D was introduced at 50 ° C and dispersed under stirring. The fluid obtained was refrigerated with stirring. An emulsion was obtained which, by regular application on the skin, improves cellular renewal.
TEST A cellular viability test on reconstructed skin (EPISKIN TM) was carried out with a support which is an emulsified gel based on AMPS ostacerin (comparative) and with an emulsion according to the invention. Tolerance is the better the greater the cell viability. The cell viability results are given in the following table.
This test shows that the emulsion according to the invention makes it possible to significantly increase the tolerance of the salicylic acid derivatives.
It is noted that in relation to this date, the best method known to the applicant, to implement said invention is that which is clear from the manufacture of the objects to which it refers. Having described the invention as above, the content of the following is claimed as property.
Claims (18)
1. Cosmetic and / or dermatological composition, in the form of an oil-in-water emulsion, characterized in that it has a pH between 4 and 7, and that it contains (i) salicylic acid and / or at least one derivative of salicylic acid, (ii) ) at least one ester of fatty acid and glucose and / or alkyl glucose, and (iii) at least one oxyethylenated ether of fatty acid and glucose and / or alkyl glucose.
2. Composition according to the preceding claim, characterized in that the fatty chain in the fatty acid ester and (alkyl) glucose or oxyethylenated ether of fatty acid and (alkyl) glucose comprises from 8 to 30 carbon atoms.
3. Composition according to claim 1 or 2, characterized in that the fatty acid ester and glucose or alkyl glucose ester are chosen from fatty esters of methylglucoside.
4. Composition according to the preceding claim, characterized in that the fatty ester of methylglucoside is chosen from the group consisting of the methylglucoside and oleic acid diester, the mixed ester of methylglucoside and the mixture of oleic acid / hydroxystearic acid, the methylglucoside and acid ester isostearic, the ester of methylglucoside and lauric acid, the ester of methylglucoside and isostearic acid, the mixture of monoster and diester of methylglucoside and isostearic acid, the mixture of monoster and diester of methylglucoside and stearic acid and their mixtures .
5. Composition according to any one of the preceding claims, characterized in that the amount of fatty acid ester (s) and glucose or alkylglucose ranges between 0.1% and 10% by weight, relative to the total weight of the composition.
6. Composition according to any one of the preceding claims, characterized in that the oxyethylenated ether of fatty acid and of glucose or of alkylglucose comprises from 10 to 100 oxyethylenated groups.
7. Composition according to any one of the preceding claims, characterized in that the oxyethylated ether of fatty acid and glucose or alkyl glucose is selected from the oxyethylenated ethers of fatty acid and methyl glucose.
8. Composition according to the preceding claim, characterized in that the oxyethylenated ether of fatty acid and of glucose or of alkylglucose is chosen from the group consisting of polyethylene glycol ether of methyl glucose and stearic acid in approximately 20 moles of ethylene oxide, ether of polyethylene glycol of the mixture of monoster and diester of methyl glucose and stearic acid in about 20 moles of ethylene oxide and mixtures thereof.
9. Composition according to any one of the preceding claims, characterized in that the amount of oxyethylenated ether (s) of fatty acid and (alkyl) glucose ranges between 0.1% and 10% by weight relative to the total weight of the composition .
10. Composition according to any one of the preceding claims, characterized in that the salicylic acid derivative is a derivative of formula (I) or a salt of said derivative: s in which: Ri represents hydrogen or an aliphatic, alkoxy, ester or ketoxy chain, saturated, linear, branched or cyclized, an unsaturated chain bearing one or more double bonds conjugated or not, these chains comprising from 1 to 22 carbon atoms. carbon and can be substituted by at least one substituent selected from the halogen atoms, the trifluoromethyl group, the hydroxyl groups in free form or esterified by an acid having from 1 to 6 carbon atoms or by a carboxyl function, free or esterified by a lower alcohol having from 1 to 6 carbon atoms; R2 represents a hydroxyl group or an ester function of formula (II): where R4 represents a saturated aliphatic group or an alkenyl group having from 1 to 18 carbon atoms, R3 represents hydrogen or a straight or branched chain, saturated or unsaturated, having from 2 to 30 carbon atoms, optionally comprising one or several substituents.
11. Composition according to any one of the preceding claims, characterized in that the salicylic acid derivative is chosen from n-octanoyl-5-salicylic acid, n-decanoyl-5-salicylic acid, n-dodecanoyl-5-salicylic acid, n-octyl-5-salicylic acid , n-heptyloxy-5-salicylic acid, 5-tert-octylsalicylic acid, 5-butoxysalicylic acid, 5-ethoxysalicylic acid, 5-methoxysalicylic acid, 5-propoxysalicylic acid, 5-methylsalicylic acid, 5-ethylsalicylic acid, 5-pro? ilsalicylic acid, salts of these acids, cetyl salicylate, dodecyl salicylate, tridecyl salicylate and mixtures thereof.
12. Composition according to any one of the preceding claims, characterized in that the amount of salicylic acid and / or derivative (s) of salicylic acid ranges between 0.001 and 10% by weight relative to the total weight of the composition.
13. Composition according to any one of the preceding claims, characterized in that the oily phase represents from 1 to 50% by weight with respect to the total weight of the composition.
14. Composition according to any one of the preceding claims, characterized in that it also contains at least one gelling agent.
15. Cosmetic treatment procedure for the protection, treatment, cleaning and / or make-up of the skin and / or mucous membranes and / or keratin fibers, characterized in that it consists of applying to the skin and / or mucous membranes and / or the keratin fibers, a composition according to any one of the preceding claims.
16. Cosmetic treatment method for combating the signs of skin aging and / or improving the brightness of the color and / or smoothing the skin of the face and / or body and / or treating wrinkles and small wrinkles of the skin and / or to stimulate the process of epidermal renewal, characterized in that it consists in applying a composition according to any one of claims 1 to 14 on the skin.
17. Use of the composition according to any one of claims 1 to 14, for the manufacture of a dermatological composition intended to combat the signs of skin aging and / or to combat against acne and / or to combat against skin disorders.
18. Cosmetic use of the composition according to any of claims 1 to 14 > for little by little treatment of human skin.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9810472 | 1998-08-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA99007373A true MXPA99007373A (en) | 2000-10-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6281203B1 (en) | Cosmetic and/or dermatological composition containing salicyclic acid derivative and its use | |
US6328987B1 (en) | Cosmetic skin care compositions containing alpha interferon | |
US6124364A (en) | Desquamation/epidermal renewal of the skin and/or combating skin aging | |
US5141741A (en) | Anti-sunburn skin-care preparation | |
US20100215726A1 (en) | Compositions for Diminishing the Appearance of Wrinkles | |
US20020187174A1 (en) | Cosmetic or dermatological composition in the form of a dispersion of an oily phase and an aqueos phase, stabilized with cubic gel particles | |
EP1216696B1 (en) | Method for reducing the appearance of dark circles under the eyes | |
US6645514B1 (en) | Increasing skin cell renewal with water-soluble Vitamin E | |
JP2007536205A (en) | Cosmetic or dermatological composition for inhibiting skin aging phenomenon | |
PL177769B1 (en) | Cosmetic and/or dermatological composition containing salicylic acid derivatives and method of stabilising such derivatives | |
EP0440058B1 (en) | Cosmetic composition | |
JP2000191426A (en) | Usage of n-acylamino acid compound as texturing agent | |
US20030095991A1 (en) | Treatment for skin | |
KR20020027198A (en) | Method for reduction of inflammation and erythema | |
EP0970690A1 (en) | Cosmtic and/or dermatological composition containing salicylic acid derivatives and process for their introduction in an aqueous composition | |
JP2004131401A (en) | Skin cosmetic | |
EP1192940A1 (en) | Compositions and methods for promoting clear skin using an alkanolamine | |
US20050281853A1 (en) | Skin compatible cosmetic compositions and delivery methods therefor | |
JP3643690B2 (en) | Skin preparation | |
KR20030005258A (en) | Use of alcohol dehydrogenase inhibitors for cosmetic treatment of keratinous materials | |
JPH07300404A (en) | Composition for cosmetic and/or dermatosis and method for using it | |
MXPA99007373A (en) | Cosmetic and/or dermatological composition containing salicylic acid or its derivatives and its use | |
JPH08507762A (en) | Use of trans-urocaninic acid as an antioxidant and for the prevention and treatment of skin aging | |
JP2002087928A (en) | Humectant for makeup and cosmetic | |
KR100457181B1 (en) | Skin rejuvenation cosmetic composition without skin irritation |